KURA Company Profile and Key Details

KURA has shown weak momentum, losing -6.22% over the past week and -12.6% over the past quarter, though year-to-date performance is down -17.23%. Short-term trend indicators are mixed aligned (SMA20 5.57%, SMA50 -4.59%, SMA200 4.0%). The stock’s 14-day RSI is 52.72 (neutral), while the ATR of 0.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -30.74% below its high and over 59.89% above its low. Average 10-day trading volume of 990.88 thousand shares is below the 3-month average of 1.73 million, indicating normal recent market interest.

Kura Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $15.18. This means the shares are trading below this model’s fair value.

Kura Oncology, Inc. (NASDAQ:KURA) closed at $9.31 USD, losing -$0.84 (-8.28%) from the previous close of $10.15. The stock is currently mid-range between its 52-week high and low $5.45 and $12.49. With a market capitalization of about $826.49 million, Kura Oncology, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.35). Key stats such as the average daily volume over the past year has been around 1.74 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Kura Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Troy Wilson, the company employs approximately 260 people and listed since September 16, 2015. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

Kura Oncology, Inc. generated EPS of -$2.48 over the past year. Five-year average earnings growth is -6.05%. Wall Street analysts project EPS growth of -6.31% annually over the next five years. The latest quarter delivered EPS of -$0.83. The next quarter is forecast at -$0.64. Next year's EPS is expected at -$8.47. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $15.00. The high target offers 294.09% upside. The low target suggests 47.78% downside. The mean target is $29.36. This offers 189.26% upside. Kura Oncology, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -5.68%. The prior quarter beat by 27.78%. Over the last six quarters, Apple has recorded several small beats. These include -66.15% in February 26, 2025.

Kura Oncology, Inc. has 88.77 million shares outstanding. The public float is 70.42 million shares, elevated short interest at 15.88% of float. This equals 13.73 million shares. The short ratio is 7.67 days. Institutional investors hold 98.68% of the float. Insiders own 1.43%. EcoR1 Capital Fund Qualified, L.P. holds 4.41 million shares, GUALBERTO ANTONIO has 339.97 thousand shares and WILSON TROY EDWARD has 246.85 thousand shares. Over the past six months, insider transactions show net selling. They sold 111.48 thousand shares across 11 transactions.

Kura Oncology, Inc. trades at a P/E ratio of -2.77, slightly below the S&P 500 average, with a price-to-sales ratio of 11.5 and a price-to-book ratio of 7.62 trading at moderately above to book value. The P/FCF stands at -9.75, also above market averages.

Kura Oncology, Inc. (NASDAQ:KURA) shares are down -17.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kura Oncology, Inc. trading at a premium to the broader market with a P/E of -2.77. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $29.94, suggesting 194.98% upside. Our AI forecast model points to short-term weakness (-11.43% over two weeks), a medium-term rise (87.59% over three months), and a longer-term gain (180.79% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Kura Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.43%, with price expected at $8.99 by August 10, 2026, within a range of $8.60 to $9.40 3-Month Outlook: Projected rise of 87.59%, reaching $19.04 by October 23, 2026, with a range of $18.73 to $19.41. 1-Year Outlook: Projected gain of 180.79%, with price at $28.50 by July 27, 2027, within a range of $17.91 to $41.73.